Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366269 | 0.82 | BRD4 (0.43) | BRD4BRD2PIK3CDL3MBTL1 | |
| SCHEMBL20531775 | 0.74 | PREP (0.33) | — | |
| SCHEMBL30786361 | 0.73 | BCAT2 (0.37) | — | |
| SCHEMBL6449914 | 0.72 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL15161544 | 0.71 | BRD4 (0.44) | BRD4BRD2PIK3CDL3MBTL1 | |
| SCHEMBL5962649 | 0.70 | — | — | |
| SCHEMBL21389245 | 0.69 | KMT2A (0.42) | BRD4BRD2PIK3CD | |
| SCHEMBL2930849 | 0.69 | BRD4 (0.46) | BRD4BRD2PIK3CD | |
| SCHEMBL6122067 | 0.69 | BRD4 (0.46) | BRD4BRD2PIK3CD | |
| SCHEMBL6199346 | 0.69 | GRM5 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912692-B2 | Substituted S-alaninate derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-27 | — | — | US | disclosed |
| CN-117043164-A | Imidazopyridazine or pyrazolopyrimidine compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-3154976-A2 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1048669-A1 | CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912692-B2 | Substituted S-alaninate derivatives | AAAS, ALAD, AASDHPPT | BRD4 4805/4885BRD2 4803/4885PIK3CD 2257/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | BRD4 265/4885BRD2 242/4885PIK3CD 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.